United Therapeutics Corporation

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
233.8 ^USD	-0.89%		-1.71%	+6.35%

Apr. 23	United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing	MT
Apr. 23	United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says	MT

United Therapeutics Corporation : To Report First Quarter 2018 Financial Results Before The Market Opens On Wednesday, May 2, 2018

April 24, 2018 at 06:06 am EDT

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 24, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its first quarter 2018 financial results before the market opens on Wednesday, May 2, 2018.

United Therapeutics will host a teleconference on Wednesday, May 2, 2018, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406, and using access code: 5778455.

This teleconference is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm. [uthr-g]

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.

View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-report-first-quarter-2018-financial-results-before-the-market-opens-on-wednesday-may-2-2018-300634871.html

SOURCE United Therapeutics Corporation

Latest news about United Therapeutics Corporation

United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing	Apr. 23	MT
United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says	Apr. 23	MT
United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing	Apr. 19	MT
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing	Apr. 17	MT
United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing	Apr. 15	MT
United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing	Apr. 11	MT
United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing	Apr. 09	MT
United Therapeutics Insider Sold Shares Worth $6,957,709, According to a Recent SEC Filing	Apr. 05	MT
United Therapeutics Insider Sold Shares Worth $1,394,248, According to a Recent SEC Filing	Apr. 04	MT
Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension	Apr. 01	MT
Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling	Apr. 01	DJ
United Therapeutics Corporation Announces Extension of Credit Agreement	Mar. 29	CI
United Therapeutics Insider Sold Shares Worth $7,375,339, According to a Recent SEC Filing	Mar. 27	MT
United Therapeutics Corporation announces an Equity Buyback for $1,000 million worth of its shares.	Mar. 25	CI
United Therapeutics Insider Sold Shares Worth $7,100,981, According to a Recent SEC Filing	Mar. 25	MT
United Therapeutics Authorizes Accelerated $1 Billion Stock Buyback Through Citigroup	Mar. 25	MT
United Therapeutics Corporation authorizes a Buyback Plan.	Mar. 23	CI
United Therapeutics Insider Sold Shares Worth $1,418,726, According to a Recent SEC Filing	Mar. 22	MT
United Therapeutics Insider Sold Shares Worth $7,088,196, According to a Recent SEC Filing	Mar. 21	MT
United Therapeutics Insider Sold Shares Worth $7,209,192, According to a Recent SEC Filing	Mar. 15	MT
Transcript : United Therapeutics Corporation Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 01:40 PM	Mar. 12
United Therapeutics Insider Sold Shares Worth $7,232,241, According to a Recent SEC Filing	Mar. 11	MT
United Therapeutics Insider Sold Shares Worth $1,424,309, According to a Recent SEC Filing	Mar. 07	MT
United Therapeutics Insider Sold Shares Worth $3,705,423, According to a Recent SEC Filing	Mar. 05	MT
Transcript : United Therapeutics Corporation Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 12:50 PM	Mar. 05

Chart United Therapeutics Corporation

Duration

Period

More charts

Company Profile

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for United Therapeutics Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

233.8 USD

Average target price

285.5 USD

Spread / Average Target

+22.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B
IQVIA HOLDINGS INC.	+1.51%	42.59B
MODERNA, INC.	+8.57%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B
BIO-TECHNE CORPORATION	-16.98%	9.85B

Other Biotechnology & Medical Research